Literature DB >> 8787937

Body composition and tissue distributions in growth hormone deficient adults before and after growth hormone treatment.

L Lönn1, G Johansson, L Sjöström, H Kvist, A Odén, B A Bengtsson.   

Abstract

This study examines short and long-term effects of recombinant human growth hormone (rhGH) on body composition and regional tissue distributions by using a multicompartment technique based on computed tomography. Part I includes nine subjects aged 46 +/- 9 years with adult onset GH deficiency who were examined before and in the end of 6 months treatment with rhGH (0.4 U.kg-1.week-1) in a double-blind crossover trial. Part II is an ongoing open trial including seven of the males in part I. They were treated with rhGH (0.25 U.kg-1.week-1) over an additional period of 24 months. Adipose tissue (AT) was reduced by 4.7 kg (p < 0.01) while the muscle plus skin compartment (M) and visceral organs (V) were increased by 2.4 (p < 0.05) and 0.7 kg (p < 0.01), respectively, over 6 months of treatment with a high rhGH dose. A preferential lipid mobilization occurred in the visceral and subcutaneous trunk depots resulting in a changed AT distribution. Muscles of legs and arms increased while the increase of trunk muscles did not reach significance. The body composition changes were maintained over 2 years additional treatment. The preferential loss in visceral AT was further pronounced while other changes in tissue distributions observed during the first 6 months tended to be reversed on the lower rhGH dosage. It is concluded that growth hormone has profound and discordant effects on AT, M and V and with associated changes in tissue distributions. The beneficial effects on body composition seen in short-term treatment is preserved throughout an additional 24 months period of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787937     DOI: 10.1002/j.1550-8528.1996.tb00511.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  8 in total

1.  Metabolic effects of discontinuing growth hormone treatment.

Authors:  F J Cowan; W D Evans; J W Gregory
Journal:  Arch Dis Child       Date:  1999-06       Impact factor: 3.791

2.  Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome.

Authors:  Antonio Mancini; Chantal Di Segni; Carmine Bruno; Giulio Olivieri; Francesco Guidi; Andrea Silvestrini; Elisabetta Meucci; Patrick Orlando; Sonia Silvestri; Luca Tiano; Alfredo Pontecorvi
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

Review 3.  A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I.

Authors:  Klara Sjögren; John-Olov Jansson; Olle G P Isaksson; Claes Ohlsson
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 4.  Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.

Authors:  Lindsey J Anderson; Jamie M Tamayose; Jose M Garcia
Journal:  Mol Cell Endocrinol       Date:  2017-06-09       Impact factor: 4.102

Review 5.  Effects of GH and insulin-like growth factor-I on body composition.

Authors:  J Svensson; L Lönn; G Johannsson; B A Bengtsson
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 6.  Clinical evaluation of the overweight patient.

Authors:  G A Bray; D H Ryan
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.925

7.  Insulin Sensitivity Is Not Decreased in Adult Patients With Hypopituitarism Without Growth Hormone Replacement.

Authors:  Alejandro Rosell Castillo; Aglecio Luiz de Souza; Sarah Monte Alegre; Yeelen Ballesteros Atala; Denise Engelbrecht Zantut-Wittmann; Heraldo Mendes Garmes
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-07       Impact factor: 5.555

8.  Fifteen years of GH replacement improves body composition and cardiovascular risk factors.

Authors:  Mariam Elbornsson; Galina Götherström; Ingvar Bosæus; Bengt-Åke Bengtsson; Gudmundur Johannsson; Johan Svensson
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.